This is the authors' abstract. We don't add key points for this paper.
Akkermansia muciniphila(A. muciniphila) has drawn much attention as an important gut microbe strain in recent years.A. muciniphilacan influence the occurrence and development of diseases of the endocrine, nervous, digestive, musculoskeletal, and respiratory systems and other diseases. It can also improve immunotherapy for some cancers.A. muciniphilais expected to become a new probiotic in addition toLactobacillusandBifidobacterium. An increase inA. muciniphilaabundance through direct or indirectA. muciniphilasupplementation may inhibit or even reverse disease progression. However, some contrary findings are found in type 2 diabetes mellitus and neurodegenerative diseases, where increasedA. muciniphilaabundance may aggravate the diseases. To enable a more comprehensive understanding of the role ofA. muciniphilain diseases, we summarize the relevant information onA. muciniphilain different systemic diseases and introduce regulators ofA. muciniphilaabundance to promote the clinical transformation ofA. muciniphilaresearch.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: